CN110167586B - 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 - Google Patents

作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 Download PDF

Info

Publication number
CN110167586B
CN110167586B CN201780080962.4A CN201780080962A CN110167586B CN 110167586 B CN110167586 B CN 110167586B CN 201780080962 A CN201780080962 A CN 201780080962A CN 110167586 B CN110167586 B CN 110167586B
Authority
CN
China
Prior art keywords
tumor
cancer
arenavirus
antigen
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780080962.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167586A (zh
Inventor
莎拉·施密特
克劳斯·奥尔林格
桑德拉·斯蒂芬妮·林
卢卡斯·罗兰·弗拉茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InnoTech Biotech Company
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of CN110167586A publication Critical patent/CN110167586A/zh
Application granted granted Critical
Publication of CN110167586B publication Critical patent/CN110167586B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780080962.4A 2016-11-04 2017-11-03 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 Active CN110167586B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662417865P 2016-11-04 2016-11-04
US201662417891P 2016-11-04 2016-11-04
US62/417,865 2016-11-04
US62/417,891 2016-11-04
PCT/EP2017/078149 WO2018083220A2 (en) 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Publications (2)

Publication Number Publication Date
CN110167586A CN110167586A (zh) 2019-08-23
CN110167586B true CN110167586B (zh) 2024-01-30

Family

ID=60452580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080962.4A Active CN110167586B (zh) 2016-11-04 2017-11-03 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Country Status (7)

Country Link
US (2) US20200206334A1 (https=)
EP (1) EP3534943A2 (https=)
JP (2) JP2019533690A (https=)
CN (1) CN110167586B (https=)
AU (1) AU2017353443B2 (https=)
CA (1) CA3039356A1 (https=)
WO (1) WO2018083220A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
CA3236106A1 (en) * 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors;Bryant G. Wieking et al;《Cancer Gene Ther.》;第第19卷卷(第第10期期);第667-674页 *
Anti-PD-1 therapy in melanoma;Blanca Homet et al;《Semin Oncol》;第1-32页 *
Immunopotentiation with low-dose cyclophosphamide in the active speci®c immunotherapy of cancer;Katherine K. Bass et al;《Cancer Immunol Immunother》;第第47卷卷;第1-12页 *
Phase I Trial of Seneca Valley Virus (NTX-010) in Children With Relapsed/Refractory Solid Tumors: A Report of the Children’s Oncology Group;Michael J. Burke et al;《Pediatr Blood Cancer》;20141012;第62卷;第743-750页 *

Also Published As

Publication number Publication date
CA3039356A1 (en) 2018-05-11
CN110167586A (zh) 2019-08-23
JP2019533690A (ja) 2019-11-21
JP2023029898A (ja) 2023-03-07
US20200206334A1 (en) 2020-07-02
AU2017353443A1 (en) 2019-05-02
WO2018083220A2 (en) 2018-05-11
AU2017353443B2 (en) 2024-11-14
EP3534943A2 (en) 2019-09-11
US20250009860A1 (en) 2025-01-09
WO2018083220A3 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CN110167586B (zh) 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒
CN108697775B (zh) 作为癌症疫苗的沙粒病毒颗粒
US20200113995A1 (en) Arenavirus particles to treat solid tumors
CN107921117B (zh) Hpv疫苗
US20250073324A1 (en) Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
CA3213083A1 (en) Arenaviruses used in treatments of prostate cancer
US20260061044A1 (en) Mutated Influenza Virus, Pharmaceutical Composition, and Use
US20250057931A1 (en) Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
HK40070799A (en) Arenavirus particles as cancer vaccines
HK1260579B (en) Arenavirus particles as cancer vaccines
HK1260579A1 (en) Arenavirus particles as cancer vaccines
WO2025191169A1 (en) Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment
TR01 Transfer of patent right

Effective date of registration: 20260414

Address after: New York State, USA

Patentee after: InnoTech Biotech Company

Country or region after: U.S.A.

Address before: Austria Vienna

Patentee before: HOOKIPA Biotech GmbH

Country or region before: Austria